Genmab — November 2017
-
Late Breaking må vel komme her når den er frigivet. http://www.hematology.org/Annual-Meeting/Abstracts/2853.aspx
-
som jeg forstår det, så var den 14. kun godkendelse som kvalificeret, men her snart udvælges 6. Man kunne vel forestille sig af der er flere end 6 kvalificerede ansøgere, så vi kan skuffes her om lidt. Jeg ser jeres og Novod's optimisme, men vi kan vel endnu ikke være sikre Jeg håber det bedste, har stadig masser af GEN
-
Genmab Announces European Regulatory Submission for Daratumumab in Front Line Multiple Myeloma
-
• Application to broaden label for daratumumab in front line multiple myeloma submitted to EMA
• Submission based on data from Phase III ALCYONE study
• Genmab to receive USD 3 million in milestone payments from Janssen -
"We are very pleased about this submission, which marks the first application for the use of daratumumab for patients with newly diagnosed multiple myeloma. We look forward to working with both Janssen and the EMA so that daratumumab can potentially become available for a broader group of multiple myeloma patients," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
-
-
Jeg ved det ikke JKY, men den er heller ikke så stor.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind